Dr. Jennifer Nelson explains how Kaiser Permanente scientists are helping the CDC and FDA keep an eye out for rare adverse events.
The investigational vaccine that KPWHRI’s team first tested shows an efficacy rate of about 94% as research continues.
KPWHRI responded to the COVID-19 hurricane with actions to improve health worldwide.
In a Viewpoint for JAMA, KPWHRI’s Dr. Mike Jackson plans ahead to meet the challenges of continuing to evaluate new vaccines.
The institute is participating in NIAID tests of Moderna and Johnson & Johnson vaccines.
The investigational mRNA vaccine is also well tolerated, according to trial led by Kaiser Permanente Washington researcher and others.
Can lessons from Immunity Community help build acceptance of COVID-19 vaccines? Clarissa Hsu, PhD, thinks so.